Correction: Trials 23, 450 (2022)

https://doi.org/10.1186/s13063-022-06255-3


Following the publication of the original article [1], a correction is needed in the description of the measurement of impairment on page 8, paragraph 2 and in the corresponding reference [50] as shown below.

Incorrect statement: “A secondary outcome will be impairment as measured by the Sheehan Disability Scales (SDS) [50], a self-report measure of impairment due to mental and physical health in four life areas in the prior 2 weeks.

Incorrect reference: “50. Sheehan DV, Mancini M, Wang J, Berggren L, Cao H, Dueñas HJ, et al. Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors. Hum Psychopharmacol. 2016;31(1):53–63. https://doi.org/10.1002/hup.2500 .

Correct statement: “A secondary outcome will be impairment as measured by self-report questions based on the Army STARRS survey [50] of role impairment due to mental and physical health in four life areas in the prior 2 weeks.”

Correct reference: “50. Ursano RJ, Colpe LJ, Heeringa SG, Kessler RC, Schoenbaum M, Stein MB; Army STARRS collaborators. The Army study to assess risk and resilience in servicemembers (Army STARRS). Psychiatry. 2014;77(2):107–19. https://doi.org/10.1521/psyc.2014.77.2.107 ”.

The original article has been corrected.